Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02412696

Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)

This study is testing the hypothesis of whether continuous positive airway pressure (CPAP) therapy improves placental histopathology and secretory function. The main aims of the study are to identify shared mechanisms between obstructive sleep apnea and preeclampsia, both common highly morbid conditions.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

Patients will be recruited from multiple community and hospital-based practices that care for pregnant women. Subjects will be given a physical exam, have measurements taken, answer questionnaires and then will be screened using a home sleep apnea test (HSAT) Type III device. Those diagnosed with Obstructive Sleep Apnea will then be randomized to one of two groups (below).

Both groups will have:

  • blood testing for placenta-secreted circulating markers
  • placental histopathological and immunohistochemistry examination of placental expression of markers.

Both groups will answer sleep and mood questionnaires, have blood pressure, blood glucose and activity / sleep watch monitoring and will receive an educational session on pregnancy health.

Randomization groups include:

  • Nasal dilator strips: Participants receiving nasal dilator strips will be monitored by need for refill of supplies and periodic phone calls.
  • CPAP + nasal dilator strips: Subjects randomized to positive airway pressure (PAP) therapy will receive auto-titrating PAP. Pressure requirements will be monitored remotely and pressure modified as needed. PAP adherence will be determined subjectively and objectively. This group will also receive nasal dilator strips as described above.

All subjects will receive small gift incentives such as baby-related items. Monetary incentives will also be issued at data collection points.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant snorers without obstructive sleep apnea, have a BMI >30 kg/m2 at recruitment
  • >18 years of age
  • <13 completed weeks of gestation (confirmed by last menstrual period or early pregnancy dating ultrasound during qualification)
  • Intention to reside locally and deliver at Women and Infants Hospital of Rhode Island
  • Ability to give informed consent.

Exclusion criteria

  • Unable to meet inclusion criteria, Incompetent cervix / cerclage (likelihood of severe preterm delivery affecting study aims)
  • Inability to tolerate PAP therapy
  • Serious physical or mental illness or condition that would affect participation
  • Drowsy driving
  • Severe hypoxemia on sleep study
  • Advanced cardiac disease or arrhythmias that may benefit from PAP therapy
  • Chronic lung disease and / or respiratory failure.
  • Twin pregnancies
  • Fetuses with congenital anomalies
  • Severe hypertension at enrollment

Treatment and study plan

Positive Airway Pressure

Device

Auto-titrating PAP + nasal dilator strips during sleep

Nasal Dilator Strips

Other

Nasal dilator strips

Primary outcomes

  1. Alterations in circulating placenta-secreted markers.

    Time frame: up to 6 months

    Placenta secreted markers that have been linked to preeclampsia as well as angiogenic and anti-angiogenic markers will be measured longitudinally during the course of pregnancy.

  2. Changes in placental histopathology for markers of malperfusion and placental expression of markers

    Time frame: Placenta collected at time of delivery

    Placental morphology and histopathology will be examined by 3 perinatal pathologists, blinded to each other's reading and to intervention arm. Immunohistochemistry will be used to examine placental expression of certain markers.

Secondary outcomes

  1. Change in 24-hour Ambulatory mean diurnal and nocturnal blood pressure measurements

    Time frame: Prior to randomization, then at approximately 3 months, and 6 months later

    A 24 blood pressure monitor will be used to measure changes in daytime and nighttime average blood pressure.

  2. Change in a composite of adverse pregnancy outcomes

    Time frame: 8 months, delivery and 2 weeks postpartum

    Pregnancy outcomes defined as gestational hypertension, gestational diabetes and preterm birth (birth prior to 37 completed weeks of pregnancy will be analyzed as a composite outcome

Sponsors and collaborators

Lead sponsor

The Miriam Hospital

Other

Collaborators

  • Brigham and Women's Hospital
  • Brown University
  • Rhode Island Hospital
  • Women and Infants Hospital of Rhode Island

Registry information

Official study title

Placental Role in Mediating Adverse Outcomes in Obstructive Sleep Apnea

Acronym: PAP-SAP

Important dates

Study start
2015
Primary completion
2020
Study completion
2025
First posted
Apr 9, 2015
Registry last updated
Nov 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.